New medication for the treatment of drug-resistant tuberculosis are available in Turkmenistan

Ashgabat, Mar 2, 2018: The development of new medicines for treatment tuberculosis (TB) has been making great progress over the past ten years. The World Health Organization has recommended new medications: Bedaquiline and Delamanid for the treatment of resistant tuberculosis. Multiple drug resistance (MDR-TB) is a form of tuberculosis in which bacteria become resistant to two main first-line drugs – isoniazid and rifampicin. Extensively drug resistance (XDR-TB) is a heavier form of tuberculosis when bacteria become resistant to drugs in both the first and second lines. Each year about 500,000 people worldwide fall ill with MDR-TB, of which 10% - XDR-TB. Until recently, there were very few medications with good efficacy to treat drug-resistant tuberculosis. Treatment lasts up to two years with possible side effects, while only 50% of MDR-TB patients and 28% of patients with XDR-TB are cured. In addition, the treatment of resistant TB forms costs between $4,000 and $9,000 per patient.

Bedaquiline is the first in 40 years innovative medication for the treatment of tuberculosis. The effect of its administration occurs within 12 weeks after the start of treatment, while other medicines show results after only 18-24 months. Delamanid is a new medication for the treatment of tuberculosis. During the treatment with Delamanid the improvement of sputum occurs within 2 months of therapy. Successful treatment of resistant tuberculosis with the use of Delamanid is higher than with the treatment of similar medication, i.e. side effects occur rarer and the mortality rate is lower.

Due to the new medications, for the first time in the last 40 years patients with drug-resistant tuberculosis have a chance to cure. However, according to data of 2017, less than five percent of patients worldwide received treatment with these medications. Other patients with drug-resistant tuberculosis continue to be treated with the use of older, more toxic drugs.

In Turkmenistan, under the Global Fund grant, the new effective medications for the treatment of drug-resistant tuberculosis have been available since 2017. The cost of Bedaquiline for the treatment of one patient is $3,000, and the cost of Delamanid - $1,700, however these and other medications for the treatment of tuberculosis are provided free of charge. Bedaquiline and Delamanid combined with other so-called “reserve” drugs for the treatment of multidrug-resistant tuberculosis: clofazimine, linezolid, Imipenem, that are also available in Turkmenistan.

Access to new medications in Turkmenistan is possible due to the fact that the Government provides all possible support to the national tuberculosis control program and creates favorable conditions for the introduction of innovative methods of diagnosis and treatment of tuberculosis.

Contact person:

Nazik Avlyakulova
Communications Associate
nazik.avlyakulova@undp.org

SubscribeSubscribe

Other News

  • UNDP and State Bank for Economic Affairs hold first ever event on financing of Agenda 2030

    UNDP and State Bank for Economic Affairs hold first ever event on financing of Agenda 2030

    20-21 June 2018, Ashgabat, Turkmenistan. In conjunction with the Sustainable Development Goals (SDG) nationalization process in Turkmenistan, the United Nations Development Programme and the State Bank for Economic Affairs (TFEB) are working to improve the access of Turkmenistan to international financing and to improve its capacity to deliver and manage such financing streams effectively.

  • United Nations and Turkmenistan stakeholders discuss post-disaster needs assessment methodology

    United Nations and Turkmenistan stakeholders discuss post-disaster needs assessment methodology

    Ashgabat, May 15-16, 2018 – UN has hosted a workshop on post-disaster needs assessment (PDNA). Over 35 representatives from the national ministries, international organizations and United Nations came to discuss benefits of applying a standardized approach and methodology for conducting emergency needs assessments, formulating a recovery strategy and planning its successful implementation.

  • Inclusive mini-marathon marks the International Day of Families

    Inclusive mini-marathon marks the International Day of Families

    Ashgabat, Turkmenistan – International Day of Families celebration was a blast with one of the most inclusive mini-marathons organized in the capital. The morning of sports events was organized by UNFPA, the United Nations Population Fund, United Nations Office on Drugs and Crime and International Organization for Migration. The Ministry of Sports and Youth Policy of Turkmenistan, the Football Federation of Turkmenistan and Sports Club of People with Disabilities of Turkmenistan were the partners of the celebration.

  • SDG Center hosted a lecture on gender equality.

    SDG Center hosted a lecture on gender equality.

    Ashgabat, May 30, 2018: United Nations jointly with the Ministry of Healthcare and Medical Industry of Turkmenistan organized a lecture on Goal 5: Achieve gender equality and empower all women and girls at the Training and Methodology Centre for Sustainable Development Goals at the Institute of International Relations in the Ministry of Foreign Affairs. The lecture was delivered to the diverse group of students, faculty members and representatives of the line ministries of Turkmenistan.